The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
AbbVie exceeded analyst expectations for its second-quarter 2026 financial results, reporting higher-than-anticipated earnings and revenue. Despite this beat, the company lowered its full-year earnings per share guidance to account for costs associated with merger and acquisition activity. Following the announcement of these financial results, AbbVie's stock price rose by 12.6%.